January 3, 2024 09:25 AM ESTUpdated January 4, 07:17 AM

Roger Perlmutter lights up the biological dark, building a new pharma force in Eikon and its superpowered microscopes

Andrew Dunn

Senior Biopharma Correspondent

HAYWARD, Calif. — After two decades at the highest R&D ranks of pharma, Roger Perlmutter has a blunt explanation for why drug development so often goes …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Roger Perlmutter lights up the biological dark, building a new pharma force in Eikon and its superpowered microscopes

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

NewAmsterdam aces Phase 3 trial, but investors are skeptical

Pfizer partners with two more Flagship biotechs on obesity, cancer

Post-Hoc: RFK vs. Vivek, and the future of US drug policy

FDA updates label of 33-year-old cancer drug with new dose and warning

Novo and Viking present new MASH data, but analysts remain confident in Madrigal's Rezdiffra

Are programs with compounded GLP-1s safe for your population?

Roger Perl­mut­ter lights up the bi­o­log­i­cal dark, build­ing a new phar­ma force in Eikon and its su­per­pow­ered mi­cro­scopes

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

No­vo and Viking present new MASH da­ta, but an­a­lysts re­main con­fi­dent in Madri­gal's Rezd­if­fra

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Roger Perlmutter lights up the biological dark, building a new pharma force in Eikon and its superpowered microscopes

NewAmsterdam aces Phase 3 trial, but investors are skeptical

Pfizer partners with two more Flagship biotechs on obesity, cancer

Post-Hoc: RFK vs. Vivek, and the future of US drug policy

FDA updates label of 33-year-old cancer drug with new dose and warning

Novo and Viking present new MASH data, but analysts remain confident in Madrigal's Rezdiffra

Are programs with compounded GLP-1s safe for your population?